NASDAQ:VTGN - Vistagen Therapeutics News Headlines

$0.62
-0.01 (-1.59 %)
(As of 07/19/2019 04:00 PM ET)
Today's Range
$0.62
Now: $0.62
$0.6688
50-Day Range
$0.63
MA: $0.74
$0.8467
52-Week Range
$0.52
Now: $0.62
$2.44
Volume131,413 shs
Average Volume102,944 shs
Market Capitalization$26.42 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.17

Headlines

Vistagen Therapeutics (NASDAQ VTGN) News Headlines

Source:
DateHeadline
VistaGen Therapeutics, Inc. (NASDAQ:VTGN): Are Analysts Bullish?VistaGen Therapeutics, Inc. (NASDAQ:VTGN): Are Analysts Bullish?
finance.yahoo.com - June 27 at 8:35 AM
VistaGen Therapeutics Reports Fiscal Year 2019 Results and Provides CNS Pipeline OverviewVistaGen Therapeutics Reports Fiscal Year 2019 Results and Provides CNS Pipeline Overview
finance.yahoo.com - June 25 at 7:30 PM
VistaGen Announces Positive Preclinical Data Supporting AV-101s Potential For Treating Levodopa-Induced Dyskinesia In Patients With Parkinsons Disease, Without The Psychological Side Effects And Safety Concerns Of AmantadineVistaGen Announces Positive Preclinical Data Supporting AV-101's Potential For Treating Levodopa-Induced Dyskinesia In Patients With Parkinson's Disease, Without The Psychological Side Effects And Safety Concerns Of Amantadine
finance.yahoo.com - June 20 at 7:50 PM
VistaGen Announces Positive Preclinical Data Supporting AV-101s Potential for Treating Neuropathic Pain Comparable to Pregabalin (Lyrica(R)), without its Side EffectsVistaGen Announces Positive Preclinical Data Supporting AV-101's Potential for Treating Neuropathic Pain Comparable to Pregabalin (Lyrica(R)), without its Side Effects
finance.yahoo.com - May 30 at 6:41 PM
VistaGen Therapeutics, Inc.: VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, ChinaVistaGen Therapeutics, Inc.: VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China
www.finanznachrichten.de - May 7 at 6:59 PM
VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, ChinaVistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China
finance.yahoo.com - May 7 at 6:59 PM
VistaGens AV-101 flunks mid-stage depression study; shares down 45%VistaGen's AV-101 flunks mid-stage depression study; shares down 45%
seekingalpha.com - May 2 at 7:59 PM
Vistagen Shares Fall Under $1 After Depression Drug Flunks Midstage TrialVistagen Shares Fall Under $1 After Depression Drug Flunks Midstage Trial
finance.yahoo.com - May 2 at 7:59 PM
VistaGen Reports Top Line Results from NIMHs Exploratory Study of AV-101 Monotherapy for Treatment-Resistant DepressionVistaGen Reports Top Line Results from NIMH's Exploratory Study of AV-101 Monotherapy for Treatment-Resistant Depression
finance.yahoo.com - May 2 at 8:26 AM
The VistaGen Therapeutics (NASDAQ:VTGN) Share Price Is Down 88% So Some Shareholders Are Rather UpsetThe VistaGen Therapeutics (NASDAQ:VTGN) Share Price Is Down 88% So Some Shareholders Are Rather Upset
finance.yahoo.com - April 27 at 5:37 PM
VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019
finance.yahoo.com - April 3 at 8:00 PM
VistaGen Hails Study Results, Hiking StockVistaGen Hails Study Results, Hiking Stock
www.marketwatch.com - April 1 at 7:56 PM
Positive Pilot Phase 3 Data Position VistaGens PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety DisorderPositive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder
finance.yahoo.com - April 1 at 7:56 PM
VistaGen nabs Australian patent covering AV-101VistaGen nabs Australian patent covering AV-101
seekingalpha.com - March 28 at 7:25 PM
VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101
finance.yahoo.com - March 28 at 7:25 PM
VistaGen Therapeutics (VTGN) Investor Presentation - Slideshow - Seeking AlphaVistaGen Therapeutics (VTGN) Investor Presentation - Slideshow - Seeking Alpha
seekingalpha.com - March 21 at 7:48 PM
VistaGen Therapeutics IncVistaGen Therapeutics Inc
www.bloomberg.com - March 19 at 8:38 AM
VistaGen Therapeutics, Inc. VTGN Files An 8-K Regulation FD DisclosureVistaGen Therapeutics, Inc. VTGN Files An 8-K Regulation FD Disclosure
www.marketwatch.com - March 15 at 8:31 AM
VistaGen Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019VistaGen Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019
finance.yahoo.com - March 14 at 7:19 PM
VistaGen Therapeutics Receives Notice of Allowance for Additional U.S. Patent Regarding Methods of Production for AV-101VistaGen Therapeutics Receives Notice of Allowance for Additional U.S. Patent Regarding Methods of Production for AV-101
finance.yahoo.com - March 13 at 7:06 PM
VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019
finance.yahoo.com - March 7 at 7:30 PM
VistaGen prices stock offering at $1; shares down 20%VistaGen prices stock offering at $1; shares down 20%
seekingalpha.com - February 26 at 6:42 PM
VistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Common StockVistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
finance.yahoo.com - February 26 at 6:42 PM
VistaGen readies stock offering; shares down 3% after hoursVistaGen readies stock offering; shares down 3% after hours
seekingalpha.com - February 25 at 7:03 PM
VistaGen Therapeutics Announces Proposed Public Offering of Common StockVistaGen Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 25 at 7:03 PM
VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and HyperalgesiaVistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia
finance.yahoo.com - February 19 at 7:01 PM
VistaGen up 4% premarket on new U.S. patentVistaGen up 4% premarket on new U.S. patent
seekingalpha.com - February 13 at 6:36 PM
VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
finance.yahoo.com - February 13 at 6:36 PM
VistaGen Therapeutics Reports Fiscal 2019 Third Quarter Financial ResultsVistaGen Therapeutics Reports Fiscal 2019 Third Quarter Financial Results
finance.yahoo.com - February 12 at 7:12 PM
VistaGen Therapeutics to Present at the 21st Annual BIO CEO & Investor Conference on February 11, 2019VistaGen Therapeutics to Present at the 21st Annual BIO CEO & Investor Conference on February 11, 2019
finance.yahoo.com - February 5 at 6:29 PM
VistaGen up 5% on preclinical AV-101 data - Seeking AlphaVistaGen up 5% on preclinical AV-101 data - Seeking Alpha
seekingalpha.com - January 31 at 6:31 PM
AV-101 Stimulates the Formation of New Brain Cells in Nonclinical StudiesAV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies
finance.yahoo.com - January 31 at 6:31 PM
VistaGen Therapeutics to Present at 11th Annual Biotech ShowcaseVistaGen Therapeutics to Present at 11th Annual Biotech Showcase
finance.yahoo.com - December 27 at 5:25 PM
The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial ResultsThe Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results
feeds.benzinga.com - December 23 at 11:18 AM
Do Institutions Own VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Shares?Do Institutions Own VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Shares?
finance.yahoo.com - December 21 at 5:30 PM
VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101 - GlobeNewswireVistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101 - GlobeNewswire
globenewswire.com - December 1 at 5:01 PM
VistaGen Therapeutics (VTGN) Receives Hong Kong Patent for Methods of Production for AV-101VistaGen Therapeutics (VTGN) Receives Hong Kong Patent for Methods of Production for AV-101
www.streetinsider.com - November 29 at 5:44 PM
VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101
finance.yahoo.com - November 29 at 5:44 PM
VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of DepressionVistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression
finance.yahoo.com - November 12 at 5:09 PM
VistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial ResultsVistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial Results
finance.yahoo.com - October 29 at 5:02 PM
VistaGen Therapeutics (VTGN) Acquires Worldwide Rights to Develop and Commercialize PH10 for MDDVistaGen Therapeutics (VTGN) Acquires Worldwide Rights to Develop and Commercialize PH10 for MDD
www.streetinsider.com - October 25 at 5:30 PM
VistaGen acquires global rights to antidepressant nasal spray; shares up 2%VistaGen acquires global rights to antidepressant nasal spray; shares up 2%
seekingalpha.com - October 25 at 5:30 PM
VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a StudyVistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study
finance.yahoo.com - October 25 at 5:30 PM
VistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018VistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018
finance.yahoo.com - October 22 at 5:21 PM
VistaGen Therapeutics Appoints Dr. Michael Liebowitz to CNS Clinical and Regulatory Advisory Board in Preparation ...VistaGen Therapeutics Appoints Dr. Michael Liebowitz to CNS Clinical and Regulatory Advisory Board in Preparation ...
globenewswire.com - October 17 at 4:57 PM
VistaGen adds expert in social anxiety disorder ahead of Phase 3 development of PH94B; shares up 4% premarketVistaGen adds expert in social anxiety disorder ahead of Phase 3 development of PH94B; shares up 4% premarket
seekingalpha.com - October 15 at 5:05 PM
VistaGen Therapeutics Appoints Dr. Michael Liebowitz to CNS Clinical and Regulatory Advisory Board in Preparation for Pivotal Phase 3 Development of PH94B as the First Rapid-Acting, On-Demand Treatment of Social Anxiety DisorderVistaGen Therapeutics Appoints Dr. Michael Liebowitz to CNS Clinical and Regulatory Advisory Board in Preparation for Pivotal Phase 3 Development of PH94B as the First Rapid-Acting, On-Demand Treatment of Social Anxiety Disorder
finance.yahoo.com - October 15 at 5:05 PM
VistaGen: Expensive At 12x Its Book Value Per ShareVistaGen: Expensive At 12x Its Book Value Per Share
seekingalpha.com - October 9 at 4:56 PM
VistaGen Up on Fast Track Designation to Pain CandidateVistaGen Up on Fast Track Designation to Pain Candidate
finance.yahoo.com - October 4 at 4:53 PM
VistaGen Therapeutics (VTGN) Granted FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic PainVistaGen Therapeutics (VTGN) Granted FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
www.streetinsider.com - October 4 at 8:16 AM
This page was last updated on 7/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel